TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03532321

Intervention type: OTHER
Intervention: NA : non interventional study
Description: NA : non interventional study
Study: NCT00410956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01479439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months
Study: NCT00914667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Single Dose Warfarin 25 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin plus Fesoterodine
Description: Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
Study: NCT01427595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace
Description: oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
Study: NCT00653523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 20 mg daily
Study: NCT06309706

Intervention type: OTHER
Intervention: No intervention
Description: Just observation
Study: NCT00999869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
Study: NCT01098721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WBI-1001
Description: Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
Study: NCT02551445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual exposure to food stimuli
Description: Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
Study: NCT02010853

Intervention type: OTHER
Group type: OTHER
Intervention: IRMf
Description: evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IRMf
Description: evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months
Study: NCT01038622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 5-day L-arginine treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5-day placebo treatment
Study: NCT02461043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel; cisplatin
Description: The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation
Study: NCT00410956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Study: NCT02461043

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: radiation
Study: NCT02942433

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavior Change Communication
Description: 9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Communication
Description: 9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
Study: NCT01586949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Challenge
Description: Web-based behavioral intervention aiming to improve individuals' well-being.
Study: NCT02942433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advocacy
Description: Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
Study: NCT00492362

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ergometer exercise during hemodialysis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedometer activity outside of hemodialysis
Study: NCT03007446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib :A starting dose of apatinib was administered 500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
Study: NCT03524482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SmokeFreeText
Description: SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path2Quit
Description: Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
Study: NCT03007446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1:40mg，bid，d1-14，po，in a 21 day cycle.
Study: NCT01619397

Intervention type: DEVICE
Group type: OTHER
Intervention: Test condom with new Xanthan gum condom coating
Study: NCT01594931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine/artesunate
Description: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine/artesunate
Description: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine/artesunate
Description: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
Study: NCT02601404

Intervention type: DEVICE
Intervention: Bioresorbable scaffold (BRS)
Description: The implantation procedure of an Absorb™ is similar to a metallic stent.
Study: NCT03935802

Intervention type: RADIATION
Intervention: radiation
Study: NCT03196804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126
Description: LC28-0126

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03753672

Intervention type: DIAGNOSTIC_TEST
Intervention: preload responsiveness
Description: We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%

Intervention type: DIAGNOSTIC_TEST
Intervention: preload responsiveness
Description: We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%
Study: NCT00979810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT PET Scan
Description: The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
Study: NCT02217124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dried apples
Description: 120 calories

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: muffin
Description: 120 calories
Study: NCT04428827

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy in patients with unilateral disease
Description: Unilateral adrenalectomy in patients with unilateral disease
Study: NCT02072915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction
Study: NCT04533724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
Study: NCT04435483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment A
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment B
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment B
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment C
Description: Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib Treatment C
Description: Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
Study: NCT00956371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7746
Description: 5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7746
Description: 5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
Study: NCT01718457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobarrier
Study: NCT04734886

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938 + vitamin D
Description: 1 \* 10\^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + vitamin D
Description: Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
Study: NCT03716115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum high protein powder (Neovite)
Description: Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Glucosamine (GInNAC)
Description: N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
Study: NCT01327768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells
Description: Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
Study: NCT02991807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.
Study: NCT01082471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine 6-glucuronide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT02177994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone 1gm for intravenous infusion
Description: Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone 1gm for intravenous infusion
Description: Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
Study: NCT01131273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: 12 weeks of methadone maintenance with counseling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine-naloxone (Suboxone) for 12 weeks
Description: 12 weeks of maintenance with counseling
Study: NCT03595397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural
Description: All patients will receive mid-thoracic epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural
Description: All patients will receive mid-thoracic epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural
Description: All patients will receive mid-thoracic epidural analgesia
Study: NCT04248699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumenato
Description: tomato oleoresin obtained from yellow dry tomato pulp
Study: NCT00648635

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking 30-60 minutes to complete every 3 months.
Study: NCT02892526

Intervention type: OTHER
Intervention: Abdominoplasty with exeresis of cutaneous tissue

Intervention type: OTHER
Intervention: Collection of cutaneous tissue
Study: NCT01896024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric Management
Study: NCT04399681

Intervention type: DEVICE
Group type: OTHER
Intervention: Bedside lung ultrasound
Description: Point of care ultrasound will be used as bedside lung ultrasound to determine the patients if they have a COVID-19 pneumonia.
Study: NCT03233256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.
Description: The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
Study: NCT03716115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide will be administered daily as subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
Study: NCT04406740

Intervention type: DEVICE
Intervention: TwitchView EMG Unit
Description: The TwitchView device is a new generation electromyographic monitor that uses a disposable electrode array that combines stimulating and recording electrodes.
Study: NCT02564341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaboration with an IT enabled nurse care manager
Description: The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and academic detailing
Description: All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated access to a specialist in addictions
Description: The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
Study: NCT03699423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% atropine eye drops
Description: 0.01% atropine sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.02% atropine eye drops
Description: 0.02% atropine sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.03% atropine eye drops
Description: 0.03% atropine sulphate
Study: NCT00574314

Intervention type: OTHER
Intervention: No Intervention
Description: Participants will be consented.
Study: NCT01464138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmidomycin and Clindamycin co-administration
Description: Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)